Worldwide, venous thromboembolism (VTE) is among the leading causes of death from
cardiovascular disease, surpassed only by acute myocardial infarction and stroke. The …

Worldwide, venous thromboembolism (VTE) is among the leading causes of death from
cardiovascular disease, surpassed only by acute myocardial infarction and stroke. The …

Venous thromboembolism (VTE) is a major cause of morbidity and mortality and
anticoagulation is the cornerstone of treatment. Although effective, traditional anticoagulants …

The first-line treatment of venous thromboembolisms (VTE) is anticoagulant therapy, and
unfractionated heparin and warfarin are used in Japan. However, as both drugs require …

Venous Thromboembolism, manifested as deep venous thrombosis and pulmonary
embolism, is a common problem associated with significant morbidity, mortality, and …

Anticoagulation is recommended for prophylaxis and treatment of venous thromboembolism
(VTE)(deep vein thrombosis and pulmonary embolism) and/or arterial thromboembolism …

Effective treatment of venous thromboembolism (VTE) strikes a balance between prevention
of recurrence and bleeding complications. The current standard of care is heparin followed …

Venous thromboembolism (VTE), comprising deep vein thrombosis and pulmonary
embolism, is a common condition associated with a significant clinical and economic …

Venous thromboembolism (VTE) is a common disease associated with high risk for
recurrences, death, and late sequelae, accounting for substantial health care costs …

Anticoagulant drugs are the foundation of therapy for patients with VTE. While effective
therapeutic agents, anticoagulants can also result in hemorrhage and other side effects …